Adalimumab
Severe
Database
Drug interaction classified as: synergy.
Source: DDInter
Drug reference
Ustekinumab
Monoclonal Antibody · Immunomodulator
Monoclonal AntibodyImmunomodulator
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
- CertolizumabSevereDatabaseDDInter
- CladribineSevereDatabaseDDInter
Mechanism
Ustekinumab is an IL-12 and IL-23 inhibitor.
Indications
Moderate to severely active Crohn’s disease (when conventional therapy or therapy with adalimumab or infliximab is unsuccessful, contraindicated or not tolerated)Psoriasisplaque psoriasispsoriatic arthritismoderate-to-severe plaque psoriasisactive psoriatic arthritismoderately to severely active crohn’s diseasemoderately to severely active ulcerative colitisinduction and maintenance of remission in Crohn’s diseasemoderate-to-severe ulcerative colitis
Dosing
- Adult
- as 50 mg weekly in RA. In psoriasis, 50 mg is given twice weekly for 12 weeks. Adverse Effects: Common adverse effects include viral, bacterial, or. is 50 mg given every 4 weeks or 2 mg/kg at weeks 0 and 4, and then every 8 weeks. A higher dose of golimumab is used to treat ulcerative colitis: 200 mg. initially at week 0 followed by 100 mg at week 2 and every 4 weeks thereafter.…
Pharmacokinetics
Peak effect
Time to peak Cp is 1 to 2 weeks.
Half-life
Variable and long elimination half-life (up to 120 days).
Side effects
Common
upper respiratory tract infectionsheadachearthralgiainfectionnauseanasopharyngitis
Serious
- increased risk of serious infections
Drug interactions
Baricitinib
Severe
Database
Drug interaction classified as: others
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Etanercept
Severe
Database
Drug interaction classified as: synergy.
Source: DDInter
Fingolimod
Severe
Database
Clinical effect not specified
Source: DDInter
Golimumab
Severe
Database
Clinical effect not specified
Source: DDInter
Infliximab
Severe
Database
Clinical effect not specified
Source: DDInter
Leflunomide
Severe
Database
Clinical effect not specified
Source: DDInter
Measles Virus Vaccine Live Attenuated
Severe
Database
Clinical effect not specified
Source: DDInter
Mumps Virus Strain B Level Jeryl Lynn Live Antigen
Severe
Database
Clinical effect not specified
Source: DDInter
Natalizumab
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Monoclonal Antibody drugs
Ask House about Ustekinumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung·Verified: 2026-05-13 · House clinical team